Oova

Oova, a spinoff of Mount Sinai Hospital, uses multiplex diagnostics to measure luteinizing hormone and progesterone to predict fertility or confirm ovulation via urinalysis. The company’s advanced nanotechnology enables a wider detection range of hormone levels for precise test results.

In July 2021 the company launched the Oova Kit, a personalized at-home test kit to predict fertility, confirm ovulation, detect fertility issues like polycystic ovary syndrome (PCOS), and for pre-menopause and post-pregnancy menstrual assessment. The starter kit, made which was available for USD 129.99 as of June 2023 , includes an ergonomic handle holder, 15 urine test strips, and a smartphone app.

In June 2023, Oova introduced a new subscription package, Oova Membership, which included the Oova Kit, monthly testing strip refills, and additional benefits including personalized support via the Oova Provider network of healthcare and fertility professionals, and access to the Oova community.

Key customers and partnerships

The company served more than 75 fertility clinics as of July 2021, and plans to add the ability to measure estrogen to its HIPAA compliant platform and expand into other health verticals such as chronic diseases.

Oova joined forces with Thorne Research in 2019 to pilot its fertility monitoring tool to the latter’s network of 3 million potential users and 35,000 clinicians as of February 2019, through fertility bundles that included Thorne’s fertility supplements and an Oova diagnostic kit.

Funding and financials

In June 2023, Oova raised USD 10.3 million in a Series A funding round led by Spero Ventures. The firm will use the funding to expand its testing capabilities in response to physician requests to test additional hormones.